Edwards Lifesciences Reports Positive Eight-Year Data on RESILIA Tissue Durability

Edwards Lifesciences announced new eight-year data confirming that aortic surgical valves treated with its proprietary RESILIA tissue offer significantly better long-term durability compared to non-RESILIA bioprosthetic valves.

Presented at the Heart Valve Society Annual Meeting, the study followed 947 patients and showed 99.3% freedom from structural valve deterioration (SVD) in the RESILIA group versus 90.5% in the non-RESILIA group. Freedom from reoperation due to SVD was 99.2% with RESILIA tissue, compared to 93.9% without.

RESILIA tissue is used across a range of Edwards’ platforms, including INSPIRIS RESILIA, KONECT RESILIA, MITRIS RESILIA, and SAPIEN 3 Ultra RESILIA. Over 450,000 patients globally have been treated with these valves.

Company leaders emphasized the data’s implications for reducing reinterventions and improving lifetime management in structural heart disease. The findings build on Edwards' decades-long leadership in heart valve innovation.

For more details, visit [edwards.com](https://www.edwards.com).